JP7466907B2 - 広域スペクトルの抗ウイルス治療のための組成物及び方法 - Google Patents

広域スペクトルの抗ウイルス治療のための組成物及び方法 Download PDF

Info

Publication number
JP7466907B2
JP7466907B2 JP2020542534A JP2020542534A JP7466907B2 JP 7466907 B2 JP7466907 B2 JP 7466907B2 JP 2020542534 A JP2020542534 A JP 2020542534A JP 2020542534 A JP2020542534 A JP 2020542534A JP 7466907 B2 JP7466907 B2 JP 7466907B2
Authority
JP
Japan
Prior art keywords
cov
mers
virus
cells
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020542534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500400A5 (enExample
JP2021500400A (ja
Inventor
ユアン，シュオフェン
チャン，フック・ウー・ジャスパー
チュ，ヒン
ラウ，ジョンソン・ユ‐ナム
ユエン，クウォック・ユン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Versitech Ltd
Original Assignee
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versitech Ltd filed Critical Versitech Ltd
Publication of JP2021500400A publication Critical patent/JP2021500400A/ja
Publication of JP2021500400A5 publication Critical patent/JP2021500400A5/ja
Application granted granted Critical
Publication of JP7466907B2 publication Critical patent/JP7466907B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020542534A 2017-10-18 2018-10-16 広域スペクトルの抗ウイルス治療のための組成物及び方法 Active JP7466907B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573933P 2017-10-18 2017-10-18
US62/573,933 2017-10-18
PCT/US2018/056138 WO2019079339A1 (en) 2017-10-18 2018-10-16 COMPOSITIONS AND METHODS FOR BROAD SPECTRUM ANTIVIRAL THERAPY

Publications (3)

Publication Number Publication Date
JP2021500400A JP2021500400A (ja) 2021-01-07
JP2021500400A5 JP2021500400A5 (enExample) 2023-02-03
JP7466907B2 true JP7466907B2 (ja) 2024-04-15

Family

ID=66173467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542534A Active JP7466907B2 (ja) 2017-10-18 2018-10-16 広域スペクトルの抗ウイルス治療のための組成物及び方法

Country Status (6)

Country Link
US (1) US12213955B2 (enExample)
EP (1) EP3697404B1 (enExample)
JP (1) JP7466907B2 (enExample)
CN (1) CN111886008B (enExample)
TW (1) TWI860281B (enExample)
WO (1) WO2019079339A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089306A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
WO2020258159A1 (en) * 2019-06-27 2020-12-30 Guangdong Oppo Mobile Telecommunications Corp., Ltd. Method and device for indicating spatial relation information
US11738025B2 (en) 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
MX2022011111A (es) * 2020-03-08 2023-03-02 Humanigen Inc Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante.
US11628165B1 (en) * 2020-03-25 2023-04-18 Helen Feng Method of boosting immune system against viral infection
ES2862462B2 (es) * 2020-04-06 2023-04-27 Servicio Andaluz De Salud Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda
WO2021211738A1 (en) * 2020-04-15 2021-10-21 Sanford Burnham Prebys Medical Discovery Institute Methods and compositions for antiviral treatment
WO2021226479A1 (en) * 2020-05-07 2021-11-11 The Regents Of The University Of California Inhaled statins for treatment of viral respiratory diseases
CN116033894A (zh) * 2020-05-22 2023-04-28 卡洛斯·阿尔贝托·里维罗斯 用于减少气道粘膜中的病毒复制的系统、方法和药物使用
WO2021249240A1 (zh) * 2020-06-11 2021-12-16 养生堂有限公司 Palovarotene在抗hbv病毒治疗中的用途
WO2022006446A1 (en) * 2020-07-02 2022-01-06 The Uab Research Foundation Compositions and methods of treating conditions
CN112390731B (zh) * 2020-11-16 2022-11-25 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用
US11998562B2 (en) 2021-01-25 2024-06-04 University Of South Florida Ophthalmological formulations for the prevention of a coronavirus infection
JP2024504728A (ja) 2021-01-26 2024-02-01 サイトケアズ （シャンハイ） インコーポレイテッド キメラ抗原受容体（ｃａｒ）構築物およびｃａｒ構築物を発現するｎｋ細胞
US20220378727A1 (en) * 2021-05-14 2022-12-01 The University Of Hong Kong Dry powder formulations of tamibarotene for pulmonary and intranasal delivery
CN116891497B (zh) * 2022-04-02 2025-12-16 上海旭成医药科技有限公司 视黄酸受体激动剂、其制备方法、中间体、药物组合物和应用
CN119013012A (zh) * 2022-04-28 2024-11-22 国立大学法人东海国立大学机构 用于治疗伴随有舒张障碍的心力衰竭的药物组合物
CN119454680B (zh) * 2024-12-06 2025-06-17 华南农业大学 贝沙罗汀在制备抗prrsv或治疗猪蓝耳病的药物中的应用
CN121177272A (zh) * 2025-11-10 2025-12-23 北京市农林科学院 化合物am580在预防或治疗塞内卡病毒病中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138354A1 (en) 2014-03-10 2015-09-17 Cornell University Combination therapy for head and neck cancer
JP2017508737A (ja) 2014-02-18 2017-03-30 チルドレンズ ホスピタル ロサンゼルス 好中球減少症の治療用の組成物及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7341717B2 (en) * 2001-04-13 2008-03-11 Gpc Biotech Ag Therapeutic targets for treatment of HCV infections, methods of treating HCV infections and compounds useful therefor
CA2509955A1 (en) * 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
WO2005120479A1 (en) * 2004-06-09 2005-12-22 Gpc Biotech Ag Use of selenium or a selenium salt and a retinoid acid or a retinoid in the treatment of viral hepatitis c
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
JP2010516702A (ja) 2007-01-18 2010-05-20 エヴォルヴァ エスアー 置換１，３−ジオキサンのプロドラッグおよびそれらの使用
CN104662036B (zh) 2012-04-25 2018-11-09 华辉安健（北京）生物科技有限公司 乙肝肝炎病毒功能性受体的组成以及相关应用
EP2922572A1 (en) * 2012-11-23 2015-09-30 AB Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
WO2018054891A1 (en) * 2016-09-20 2018-03-29 Ruprecht-Karls-Universität Compounds and combinations thereof for preventing and/or treating hbv and/or hdv infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017508737A (ja) 2014-02-18 2017-03-30 チルドレンズ ホスピタル ロサンゼルス 好中球減少症の治療用の組成物及び方法
WO2015138354A1 (en) 2014-03-10 2015-09-17 Cornell University Combination therapy for head and neck cancer

Also Published As

Publication number Publication date
EP3697404A1 (en) 2020-08-26
EP3697404B1 (en) 2025-03-26
US12213955B2 (en) 2025-02-04
WO2019079339A1 (en) 2019-04-25
EP3697404A4 (en) 2021-07-21
JP2021500400A (ja) 2021-01-07
CN111886008A (zh) 2020-11-03
TW201927293A (zh) 2019-07-16
CN111886008B (zh) 2024-05-31
US20200338032A1 (en) 2020-10-29
TWI860281B (zh) 2024-11-01

Similar Documents

Publication Publication Date Title
JP7466907B2 (ja) 広域スペクトルの抗ウイルス治療のための組成物及び方法
Yuan et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target
Prajapat et al. Drug targets for corona virus: A systematic review
Nitulescu et al. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies
Xu et al. Broad spectrum antiviral agent niclosamide and its therapeutic potential
Williams et al. Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication
Chen et al. Synergistic inhibition of SARS-CoV-2 replication using disulfiram/ebselen and remdesivir
Barik New treatments for influenza
Wang et al. Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: strategies, benefits, and challenges
Wang et al. Triggering unfolded protein response by 2-Deoxy-D-glucose inhibits porcine epidemic diarrhea virus propagation
Laure et al. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model
Pillaiyar et al. The recent outbreaks of human coronaviruses: A medicinal chemistry perspective
Liu et al. Clinical HDAC inhibitors are effective drugs to prevent the entry of SARS-CoV2
Garcia-del-Barco et al. Revisiting pleiotropic effects of type I interferons: rationale for its prophylactic and therapeutic use against SARS-CoV-2
Gómez-Ríos et al. Repurposing antivirals as potential treatments for SARS-CoV-2: From SARS to COVID-19
Huang et al. Mitophagy activation targeting PINK1 is an effective treatment to inhibit zika virus replication
Tang et al. A selective SARS-CoV-2 host-directed antiviral targeting stress response to reactive oxygen species
Tang et al. Peptide-based inhibitors hold great promise as the broad-spectrum agents against coronavirus
Li et al. Differential Bioactivation Profiles of Different GS-441524 Prodrugs in Cell and Mouse Models: ProTide Prodrugs with High Cell Permeability and Susceptibility to Cathepsin A Are More Efficient in Delivering Antiviral Active Metabolites to the Lung
Hayn et al. Imperfect innate immune antagonism renders SARS-CoV-2 vulnerable towards IFN-γ and-λ
Raj et al. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19
HK40038027B (zh) 用於抗mers-冠状病毒治疗的组合物和方法
HK40038027A (en) Compositions and methods for anti-mers-coronavirus therapy
Kushwaha et al. Structural basis for the understanding of entry inhibitors against SARS viruses
Li et al. Chebulinic acid suppresses porcine epidemic diarrhea virus infection by inhibiting viral entry and viral main protease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200702

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211015

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240327

R150 Certificate of patent or registration of utility model

Ref document number: 7466907

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150